Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


England Expects Biosimilar Savings Of Up To Half A Billion

Executive Summary

With a tender and reference prices for adalimumab now in place, NHS England has raised its forecast for annual savings through biosimilar competition to half a billion pounds.



Related Content

ASBM Hits Back At British Columbia Switching Scheme
English Adalimumab Tender Marks Progress, But Is Not Perfect
UK expects to save 75% from adalimumab rivals
English contracts to save up to £150mn





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts